The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate if nitazoxanide used in combination with interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic patients by improving their sustained viral response by more than 80%.Considering that the study is being conducted in a third world country like Pakistan, the standard treatment of hepatitis C is not cost effective. The aim is to introduce a new treatment comparable in efficacy to peginterferon and also cost effective.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Services Institute of Medical Sciences, Pakistan
• Collaborator: Getz Pharma
• Treatments: Interferon-alpha; Interferons; Nitazoxanide; Ribavirin

Criteria

Inclusion Criteria:

• Hepatitis C genotype 3a

• Hepatitis C Virus(PCR)RNA Detected

• Alanine transaminase >60

• Diabetic HbA1c<8

• BMI>23

Exclusion Criteria:

• Previously treated Hepatitis C patients

• Pregnant females

• Decompensated liver disease,Child class B OR above

• Thyroid disease,Thyroid stimulating hormone>10,0.05

• Absolute neutrophil count<1500,Platelets<80,000,Hb<10g Female,<11g Male

• Severe cardiac disease,New York Heart Association2

• Moderate to severe depression assessed by Beck Depression Inventory scale